1214 GMT - Johnson & Johnson topped 4Q sales projections, but its outlook for 2025 is coming up short on the top line. The healthcare company is guiding for sales to rise between half a percentage point and 1.5%, bringing them to $89.2 billion to $90 billion total. That is below current analyst forecasts for $90.98 billion, according to FactSet. Sales would be higher were it not for impacts from acquisitions and divestitures, or foreign-currency translation, the company says. Adjusted earnings meanwhile are expected to hit $10.50 to $10.70 a share. Analysts polled by FactSet are currently forecasting $10.53 a share. Shares tick down slightly premarket. (dean.seal@wsj.com)
(END) Dow Jones Newswires
January 22, 2025 07:15 ET (12:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
